Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-698 / ECHO-303 in metastatic urothelial carcinoma
2017-002310-31Phase 3Completed
- Sponsor
- Incyte
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Pembrolizumab + epacadostat with Pembrolizumab + placebo (2 arms). Primary endpoint: Overall survival. Started Oct 2017; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2017-002310-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002310-31.